BO1 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - BioCryst Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 6.916 EUR 0.9% Market Closed

Market Cap: €2.2B

B	BioCryst Pharmaceuticals Inc XMUN:BO1	US
A	Athens Medical Center SA SWB:ACS	GR
D	DoorDash Inc NASDAQ:DASH	US
	Compass Pathways PLC NASDAQ:CMPS	UK
N	Nordic Nickel Ltd ASX:NNL	AU
	ING Bank Slaski SA F:6GF	PL
	Jupiter Fund Management PLC LSE:JUP	UK
S	Sony Group Corp F:SONA	JP
	ARMOUR Residential REIT Inc F:2AR	US
	Universal Music Group NV AEX:UMG	NL
M	Medistim ASA SWB:MD1	NO

Profitability Summary

BioCryst Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

98%

Strong 3Y Average Gross Margin

98%

Declining Gross Margin

98% > 98%

Exceptional Operating Margin

41%

Low 3Y Average Operating Margin

Operating Margin is Increasing

-34% > 41%

Negative Net Margin

-41%

Negative 3Y Average Net Margin

-27%

Net Margin is Increasing

-74% > -41%

Exceptional Free Cash Flow Margin

41%

Sustainable 3Y Average Free Cash Flow Margin

Free Cash Flow Margin is Increasing

-35% > 41%

Exceptional ROE

88%

Exceptional 3Y Average ROE

Exceptional 3Y Average ROIC

34%

ROIC is Increasing

-91% > 203%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.